Intersect ENT, Inc. IPO Research Information

Intersect ENT, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Intersect ENT, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Intersect ENT, Inc.	XENT - NASDAQ	$11.00-$13.00	$11.00	$13.20	5 milion	7/24/2014
Underwriter(s): J.P. Morgan, Piper Jaffray
Co-Manager(s): Leerink Partners, Wedbush PacGrow Life Sciences
Industry: Health Care
Filing(s): Filed 2014-06-24 Terms Added 2014-07-14

Intersect ENT, Inc. Quote & Chart - Click for current quote - XENT

About Intersect ENT, Inc. (adapted from Intersect ENT, Inc. prospectus):
They are a commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions.

This description is adapted from Intersect ENT, Inc. prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as Intersect ENT, Inc. "XENT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.